Cystic Fibrosis Buyers Club Shows the UK Government The Way
The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...
Medicines Excitement in the Netherlands – New Health Minister announces firm action on...
The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced...
Modifier la législation européenne pour mettre en œuvre la licence d’office en France
Selon le Dr Thierry Philip, Président de l’institut Curie, la hausse des prix des nouveaux traitements contre le cancer « est devenue intenable. »
L’augmentation croissante du prix...
EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
Drug Price Transparency Calls Move from South Africa to World Health Assembly
by Katrina Perehudoff and Jennifer Sellin
Over 30 states and 40 business and civil society groups debated strategies for affordable and sustainable medicines prices at...
Chile’s Technology and Knowledge Transfer Bill passes Congress with important commitments on socially responsible...
On 9 June, the Chilean Congress approved a Technology and Knowledge Transfer bill (Ley de Transferencia de Tecnología y Conocimiento) that makes important strides...
Wrapping Up 2017 – some noteworthy medicines law and policy events.
2017 was a significant year for access to medicines and other medicines policy related events. Here are a few highlights of the last 12...
TRIPS Council to discuss IP and the public interest in the context of Covid-19
The search for new treatments and vaccines needed to respond to the Covid-19 outbreak has laid bare some key issues around intellectual property (IP)...
FDA approval of injectable lenacapavir for Pre-Exposure Prophylaxis (PrEP) opens the road to ending...
On 18th June 2025, the US Food and Drug Administration (FDA) approved the use of long-acting antiretroviral medicine lenacapavir (LEN-LA), for the prevention of...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...